Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» BeiGene
BeiGene
BeiGene to go solo with cancer drug after Novartis deal termination
BeiGene to go solo with cancer drug after Novartis deal termination
Yahoo/Reuters
BeiGene
Novartis
cancer
tislelizumab
Tivimbra
Flag link:
Bristol Myers, BeiGene end legacy Celgene deal with settlement years after China ban
Bristol Myers, BeiGene end legacy Celgene deal with settlement years after China ban
Fierce Pharma
Bristol Myers Squibb
BeiGene
Celgene
Flag link:
Novartis retreats from TIGIT, handing $300M candidate back to BeiGene
Novartis retreats from TIGIT, handing $300M candidate back to BeiGene
Fierce Biotech
Novartis
anti-TIGIT
BeiGene
Flag link:
AbbVie's Imbruvica-Brukinsa patent suit may have merit, and BeiGene will likely settle: expert
AbbVie's Imbruvica-Brukinsa patent suit may have merit, and BeiGene will likely settle: expert
Fierce Pharma
AbbVie
patents
BeiGene
legal
Btk inhibitors
Flag link:
AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up
AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up
Fierce Pharma
AbbVie
Pharmacyclics
BeiGene
Brukinsa
patents
Imbruvica
blood cancer
Flag link:
BeiGene's gastric cancer drug succeeds in late-stage trial
BeiGene's gastric cancer drug succeeds in late-stage trial
Reuters
BeiGene
gastric cancer
clinical trials
tislelizumab
Flag link:
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint
NJ Business
BeiGene
New Jersey
R&D
drug manufacturing
Flag link:
BeiGene pulls out of Leap of faith, letting option on immuno-oncology candidate lapse
BeiGene pulls out of Leap of faith, letting option on immuno-oncology candidate lapse
Fierce Biotech
BeiGene
immuno-oncology
Leap Therapeutics
DKN-01
Flag link:
Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report
Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report
Fierce Biotech
Big Pharma
Novo Nordisk
Moderna Therapeutics
Gilead Sciences
BeiGene
Flag link:
BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches
BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches
Fierce Pharma
BeiGene
Brukinsa
earnings
tislelizumab
Flag link:
This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more
This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more
RAPS.org
FDA
regulatory
clinical trials
clinicaltrials.gov
Eli Lilly
donanemab
Medtronic
BeiGene
Seagen
Flag link:
BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial
BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial
Endpoints
BeiGene
Brukinsa
CLL
FDA
Imbruvica
Flag link:
Big caps bounce back for biopharma
Big caps bounce back for biopharma
EP Vantage
pharma stocks
Amgen
BeiGene
Bristol Myers Squibb
Gilead Sciences
Lantheus Holdings
Madrigal Pharmaceuticals
Merck
Moderna Therapeutics
Novo Nordisk
Prometheus Biosciences
Roche
Flag link:
ASH 2022 – pirtobrutinib leads the post-Imbruvica charge
ASH 2022 – pirtobrutinib leads the post-Imbruvica charge
EP Vantage
ASH 2022
Eli Lilly
BeiGene
Nurix Therapeutics
Brukinsa
pirtobrutinib
NX-2127
Flag link:
Go or no go? Mirati heads to the FDA
Go or no go? Mirati heads to the FDA
EP Vantage
FDA
Mirati Therapeutics
Gilead Sciences
Coherus Biosciences
Roche
Biogen
TG Therapeutics
Ipsen
Novartis
BeiGene
Cytokinetics
Flag link:
Few safe havens surface in another down quarter for biopharma
Few safe havens surface in another down quarter for biopharma
EP Vantage
biopharma stocks
COVID-19
Eli Lilly
Bristol Myers Squibb
Merck
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Neurocrine
Sarepta Therapeutics
Orion
Pfizer
GSK
Roche
Moderna Therapeutics
BeiGene
BioNTech
Novavax
CureVac
Flag link:
BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica
BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica
Fierce Pharma
BeiGene
AbbVie
JNJ
Imbruvica
blood cancers
Brukinsa
Flag link:
ESMO 2022 – the new liver cancer entrants line up
ESMO 2022 – the new liver cancer entrants line up
EP Vantage
ESMO
liver cancer
Keytruda
tislelizumab
camrelizumab
Merck
BeiGene
Novartis
Flag link:
BeiGene and Novartis Make Late-Stage Progress against Liver Cancer
BeiGene and Novartis Make Late-Stage Progress against Liver Cancer
BioSpace
Novartis
BeiGene
hepatocellular carcinoma
liver cancer
clinical trials
Flag link:
FDA Indefinitely Delays BeiGene/Novartis anti-PD-1 Esophageal Cancer Drug
FDA Indefinitely Delays BeiGene/Novartis anti-PD-1 Esophageal Cancer Drug
BioSpace
Novartis
BeiGene
FDA
tislelizumab
esophageal cancer
Flag link:
Pages
1
2
3
4
5
next ›
last »